The Design of Potent and Selective Inhibitors to Overcome Clinical Alk Mutations Resistant to Crizotinib.
Huang, Q., Johnson, T.W., Bailey, S., Brooun, A., Bunker, K.D., Burke, B.J., Collins, M.R., Cook, A., Cui, J.J., Dack, K.N., Deal, J.G., Deng, Y., Dinh, D.M., Engstrom, L.D., He, M., Hoffman, J., Hoffman, R.L., Shen, H., Johnson, P., Kania, R.S., Lam, H., Lam, J.L., Le, P., Li, Q., Lingardo, L., Liu, W., West Lu, M., Mctigue, M.A., Palmer, C.L., Richardson, P.F., Sach, N.W., Smeal, T., Smith, G.L., Stewart, A.E., Timofeevski, S.L., Tsaparikos, K., Wang, H., Zhu, H., Zhu, J., Zou, H.Y., Edwards, M.
J.Med.Chem.